BioCentury
ARTICLE | Emerging Company Profile

Dyno taking partner-heavy strategy with next-generation gene therapy vectors

With a $9M seed round and two deals, Dyno may not need to raise any more private capital

May 11, 2020 11:02 AM UTC
Updated on May 11, 2020 at 6:57 PM UTC

After two years in stealth mode, modestly-funded Dyno believes its synthetic capsid engineering platform will be best used by partners to feed their gene therapy pipelines with optimized candidates -- including two biopharmas that have already struck deals with the start-up.

On Monday, Dyno Therapeutics Inc. revealed $9 million in initial funding and partnerships with Novartis AG (NYSE:NVS; SIX:NOVN) in ocular disorders and with Sarepta Therapeutics Inc. (NASDAQ:SRPT) in muscle diseases. Both biopharmas are using Dyno’s platform, which is based on work from co-founder George Church’s lab at Harvard Medical School and the university’s Wyss Institute for Biologically Inspired Engineering, to design therapies with improved functional properties...